Strategy

Zimmer Biomet is preparing to introduce iodine-coated hip implants to international markets, offering joint replacement patients a new alternative intended to ward off infection. The company intends to broaden the platform’s reach into “knees, shoulders and other categories in due time.”

Ahead of Exact Science’s $21bn dollar acquisition by Abbott, Medtech Insight spoke to the company’s chief medical officer, Tomasz Beer, to learn more about the company’s multi-cancer early detection offering, its wider portfolio of products and to hear more about the direction of the field.

Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.

CEO Bernd Montag said a reduced Siemens stake could make Healthineers attractive to new investors.

BrainsWay advanced its Deep TMS platform with an FDA labeling expansion for adolescent MDD and the launch of a 200-patient alcohol use disorder trial. The company posted strong Q3 growth and is pursuing new indications and at-home neuromodulation through its Neuralief investment.

Analysts expect ResMed to receive substantial incremental demand from customers who switch away from Philips following its recall as well as from consumers who question Philips' reputation.

Illumina’s latest generation platform, the NovaSeq X, continues to gain traction among research and clinical customers. During the third quarter, the company placed more than 55 instruments, aligning with its target of 50 to 60 placements per quarter.

As BD refines its commercial model, it has also brought leadership transition to its finance organization. The company recently announced that executive vice president and chief financial officer Chris DelOrefice will depart BD effective Dec. 5.

Record Mako installations in the third quarter fueled growth across Stryker’s orthopedics portfolio, supporting higher revenue in the “Ortho Other” category. Executives said new product launches and software upgrades are broadening clinical applications.

Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.

Philips puts its latest “disappointing” warning letter into context, while announcing progress in regulatory performance, expanded US production and tariff resilience plans

The 15-day sensor, which is initially being introduced within a limited “Warrior” community, will not meaningfully affect 2025 results but will begin to drive both margin expansion and access to lower reimbursement markets the following year.

Delfi Diagnostics is preparing for pivotal trial results that could support FDA approval and reimbursement for its fragmentomics-based lung cancer screening test. Early data suggest strong potential to improve screening uptake and expand access to early detection.

GE HealthCare expects to fall short of its earlier set $30m revenue goal for Flyrcado in 2025. CEO Arduini attributed the slower near-term growth to a deliberate decision to focus on customer onboarding and supply reliability rather than short-term revenue.

Timing of the $533m acquisition aligns with both Nalu’s commercial maturity (‘now they have solid Medicare reimbursement’) and Boston Scientific’s readiness to expand its neuromodulation portfolio after integration of Relievant Medsystems.

Roche CEO Matthew Sause said that the company’s ambition for 2025 remains low single-digit growth in diagnostics, rising to mid-single-digit growth in 2026 as the effects of Chinese reforms begin to ease.

Inspired by his son’s battle with cancer, Neal Piper founded Luminoah to modernize enteral feeding. Its smart, pocket-sized pump tracks nutrition in real time to prevent malnutrition and improve quality of life for patients and caregivers.

As CMS seems poised to extend reimbursement for pulsed field ablation to ambulatory surgery centers, CEO Mike Mahoney said Boston Scientific has seen “strong interest” for its products in states such as Arizona and Florida, which do not require certificates of need for ablations at ASCs.

John Nugent, who heads the medtech division at Irish business development agency IDA Ireland, spoke to Medtech Insight about how the country’s 75-year focus on encouraging medtech innovation is shifting in the light of digital health, AI, tariffs, and other new challenges.

Wearables innovator Oura has launched a profile study aimed at helping the company secure FDA clearance for a blood pressure feature for its smart ring. Study participants will answer questions while wearing the ring, which the company plans to use to support the feature’s efficacy.